

# ANNUAL REPORT 2025



**WOMENinLYMPHOMA**

Supported by  Lymphoma  
Australia

# A WORD FROM OUR CHAIRS

In 2025, Women in Lymphoma (WiL) consolidated its foundations and expanded its global impact. Our network grew across education, mentorship, research, and community engagement—strengthening our collective voice for equity and leadership in lymphoma worldwide.

This year, WiL delivered a robust global education program, engaging participants from more than 35 countries through our webinar series and podcasts. We also strengthened visibility and connection through two highly successful networking events held alongside major international haematology meetings.


A major milestone was the launch of WiL's first Global Gender Equity Survey, completed by 237 haematology professionals from 34 countries. This work establishes the first quantitative baseline for understanding gender disparities in leadership, mentorship, and visibility within lymphoma. These findings now guide our advocacy efforts and discussions with international haematology societies to embed equity metrics into broader academic and professional frameworks.

Mentorship and skills development also advanced significantly. In 2025, WiL launched two flagship mentorship initiatives:

1. The WiL Academy, offering international training opportunities including hands-on exposure to CAR-T programs; and
2. The WiL Mentorship Program, piloted through the Healio platform to support structured, trackable mentor-mentee relationships across career stages.

WiL's global reach continued to expand. Membership grew to more than 1,700 members across 78 countries, reflecting a diverse and increasingly inclusive community of clinicians, researchers, educators, and champions committed to advancing equity in lymphoma.

As we look ahead to 2026, our priorities remain clear: to deepen international collaborations, expand gender equity research, scale mentorship and training programs, and continue creating inclusive opportunities for professional development. We thank our members, partners, and supporters for their commitment and invite others to join us as we continue to drive meaningful change for women in lymphoma.



**ANNA SUREDA**  
CHAIR 2025-2026



**FLORENCE BROUSSAIS**  
CHAIR 2024-2025



# OUR STEERING COMMITTEE

WiL is led by a Steering Committee of **26 women from 13 countries**, representing academic centres and lymphoma programs worldwide and includes experts in clinical research, education, stem cell transplantation, cellular therapy, and lymphoma program leadership.

## Steering Committee Members:

Dr Maia ANANIASHVILI - GEO



Dr Florence BROUSSAIS - JAP



Prof Carla CASULO - USA

Dr Adalgisa CONDOLUCI - CHE

Dr Jennifer CROMBIE - USA

Prof Kate CWYNARSKI - UK

Dr Paola GHIONE - USA



Dr Natalie GROVER - USA

Prof Eliza HAWKES - AUS

Dr Laura HILTON - CAN

Dr Laura KORIN - ARG

Dr Ann LACASCE - USA



Dr Kat LEWIS - AUS

Prof Kim LINTON - UK

Dr Carolina MAHUAD - ARG

Sharon MILLMAN - AUS

Dr Wendy OSBORNE - UK



Dr Astrid PAVLOVSKY - ARG

Dr Michelle POON - SGP

Dr Sabrina RANERO FERRARI - URY

Dr Clémentine SARKOZY - FRA

Dr Laurie SEHN - CAN



Dr Soni SMITH - USA

Dr Anna SUREDA - ESP

Prof Judith TROTMAN - AUS

Dr Meng WU - CHN



# OUR SUB COMMITTEE

WiL is supported by a Subcommittee of **18 members from 5 countries**, contributing to project coordination, education, communication, and strategic planning.

Dr Allison BARRACLOUGH - AUS  
Dr Allison BOCK - USA  
Dr Benedicte DEAU FISCHER - FRA  
Dr Irene DOGLIOTTI - ITA  
Dr Supriya GUPTA - USA  
Dr Avyakta KALLAM - USA  
Dr Swetha KAMBHAMPATI THIRUVENGADAM - USA  
Dr Supreet KAUR - USA  
Dr Amira MAROUF - USA  
Dr Patrizia MONDELLO - USA  
Dr Beth PHILLIPS - UK  
Dr Priyanka POPHALI - USA  
Dr Sumita RATNASINGHAM - AUS  
Dr Tarsheen SETHI - USA  
Dr Claire TIGER - USA  
Dr Keri TONER - USA  
Dr Pallawi TORKA - USA  
Dr Stella WILLIAMS - UK

## Expanded Organisational Framework

WiL has expanded its organisational framework with the Women in Industry Council and the Change Champions Committee, both contributing to advocacy, outreach, and strategic initiatives.



# “IF YOU CAN SEE IT, YOU CAN BE IT”

Under the banner “If you can see it, you can be it,” WiL has delivered a robust global education program.

By 2025, **70 webinars** across **16 series** featured **149 international expert presenters**, attracting **5,881 registrations** and generating **17,100 on-demand views** worldwide. These free, evidence-based sessions have amplified the visibility of women leaders and inspired early-career professionals globally.

Building on this success, WiL launched its flagship WiL Academy in 2025, developed in collaboration with NCIS, APBMT, ACTRIS, and SGH, and supported by Kite Gilead and the Eurêka Foundation. A major highlight was the Singapore CAR-T Internship, providing hands-on training in advanced cellular therapies.

WiL also expanded its Mentorship Program, piloted through the Healio platform, enabling structured, trackable mentor-mentee relationships focused on career development, research experience, and leadership skills.



In 2025, Women in Lymphoma delivered three multi-session **WiLing Wednesday** educational webinar series addressing both clinical and professional development priorities.

Series 16 focused on mantle cell lymphoma, covering frontline therapy, high-risk disease, relapsed/refractory settings, and the role of minimal residual disease.

Series 15 explored the relationship between pathogens and lymphoma, including EBV, the microbiome, infection-driven lymphomagenesis, and post-treatment infection risk.

Series 14, Demystifying Pharma, provided insights into the pharmaceutical industry, including structure, engagement, research collaboration and career pathways.

All sessions were led by internationally recognised experts and can be viewed at <https://womeninlymphoma.org/webinars>

# EDUCATION AND PUBLICATIONS

In collaboration with MedNews Week and presented in partnership with OncLive, WiL delivered the Voices in Lymphoma: Women Shaping Care virtual lecture series. This monthly program highlighted female leaders in lymphoma, addressing advances in disease management, evolving treatment strategies, and professional development.

## 2025 Topics and Presenters

- Hodgkin Lymphoma: Overview and Update : Ann LaCasce
- Comparing UK and US Approaches to First-Line Treatment in Hodgkin Lymphoma : Wendy Osborne, Sarah Rutherford
- Decoding T-Cell Lymphoma : Kerry Savage, Neha Mehta-Shah
- Strong Mentorship Opportunities : Ann LaCasce
- Insights into Marginal Zone Lymphoma : Paola Ghione, Catherine Thieblemont
- Mantle Cell Lymphoma: Evolving Strategies: Kami Maddocks, Morgane Cheminant
- Evolving Paradigms in First Relapse of DLBCL: Soni Smith, Manali Kamdar
- Follicular Lymphoma: General Concepts and First-Line Strategies : Carla Casulo, Clémentine Sarkozy

Watch the series here <https://womeninlymphoma.org/news>

A key publication milestone in 2025 was the article “Celebrating 5 years of Women in Lymphoma: a road to equality, diversity, and inclusion in the field”, published in *The Lancet Haematology*.

Read the article here <https://drive.google.com/drive/search?q=lancet>


# ADVANCING GENDER EQUITY

WiL's commitment to equity extends beyond education. In 2025, WiL completed its first Global Gender Equity Survey, engaging **237 haematology professionals** from **34 countries** to establish a baseline on disparities in leadership, mentorship, and visibility. These findings now inform advocacy efforts and discussions with international societies to embed equity metrics and drive systemic change.

Representation has improved markedly: women now feature more prominently as speakers, chairs, and committee members at major meetings including ICML, ASH, ASCO, BSH, and ESH. The creation of an Industry Sub-Committee in 2023 has opened doors for women to join advisory boards, trial steering committees, and serve as principal investigators—critical steps toward increasing female authorship and influence in clinical research.

Advocacy remains central to WiL's vision. The Change Champions Committee, comprising male allies and senior WiL leaders, exemplifies collaborative action to dismantle structural barriers and foster cultural change.





## ENGAGEMENT

Since our inception in 2019, WiL global membership has continued to grow, with the majority of members from North America, Europe, Australia and South America. 2025 saw a **40% increase** in new members.

Networking has also flourished, with **175 participants** at ICML and ASH events in 2025, and seven international networking events since 2022.

WiL's digital footprint continues to grow, with over **10,000** annual website visitors and thousands of followers across LinkedIn, X and Bluesky.



# THANK YOU

In just five years, WiL has delivered tangible progress: global membership growth, high-impact educational programs, improved representation in scientific forums, and structural advocacy initiatives that challenge inequity.

With a positive financial position, succession planning underway and new projects - including expanded mentorship cohorts, clinical trials training, and gender equity research - WiL is poised to remain a catalyst for change, empowering women, influencing policy, and setting a benchmark for diversity and inclusion in haematology worldwide.

Thank you to Lymphoma Australia for their support, as well as our 2025 sponsors, partners, members and community.

